From Lifestyle to Liver Cancer

11:35 EST 15 Nov 2017 | PR Web

The American Liver Foundation and Bayer partner again for the annual Are You At Risk? campaign.

NEW YORK (PRWEB) November 15, 2017

Liver cancer is the second-leading cause of cancer-related deaths in the world.1 Liver cancer may be talked about less than other cancer types, but it claims the lives of more than 79 Americans each day, or nearly 29,000 per year.2

A video accompanying this announcement is available at:

People often believe that liver cancer is ‘in the genes,’ when in reality, we can be put at higher risk of developing cancer by way of actions we mostly have control of – like what we eat, how much we choose to participate in physical activity, and the amount of alcohol we consume.

In 2017, it is estimated that the number of diagnosed cases of liver cancer in the U.S. will rise to nearly 40,000.2 That is why monitoring everyday lifestyle choices such as eating habits and alcohol consumption, among others, can play major roles in helping to prevent this deadly disease.

For the fourth year in a row the American Liver Foundation partnered with Bayer to launch its annual Are You At Risk? campaign. In conjunction with the campaign, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, and Thomas Nealon III, CEO of the American Liver Foundation, embarked on a nationwide media tour to provide helpful information on this deadly disease.

The program is designed to increase awareness of liver cancer and its risk factors, which include chronic viral hepatitis, morbid obesity, diabetes and alcoholic cirrhosis.3 It also aims to expand the general public’s knowledge of lifestyle factors that contribute to the disease, as well as the importance and benefits of liver cancer screenings and early detection.

For more information, please visit:

About American Liver Foundation:
The American Liver Foundation is a non-profit organization that promotes liver health and disease prevention. The mission of the ALF is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.

Bayer: Science For A Better Life:
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to

1 GLOBOCAN. Liver Cancer. Accessed November 2017.
2 American Cancer Society. Key Statistics About Liver Cancer. Accessed November 2017.
3 American Cancer Society. Liver Cancer Risk Factors. Accessed November 2017.

For the original version on PRWeb visit:


More From BioPortfolio on "From Lifestyle to Liver Cancer"

Quick Search


Relevant Topics

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...